One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
INmune Bio logo
INmune Bio INMB
$ 0.82 -7.87%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

INmune Bio Balance Sheet 2025-2011 | INMB

Brief overview of INmune Bio's financial position

The comparison uses five available annual reports from the 2021–2025 interval.

The asset base decreased -67.6%, from $99.9 million to $32.4 million. Resources became smaller over the five periods.

Asset growth of -67.6% came with a -55.2% rise in liabilities. Financial leverage became more prominent.

Equity funds 72.7% of assets versus 80.3% initially. This creates a conservative balance sheet structure.

Net debt moved below zero to -$23.7 million, reflecting surplus cash over debt.

The cash reserve occupies 76.5% of the balance sheet, previously 74.9%. It is one marker of short-term resilience.

The accumulated result is -$209 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Overall picture

The balance sheet gives no single signal for INmune Bio: some indicators are sound, while leverage or capitalization needs attention.

Annual Balance Sheet INmune Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-23.7 M -5.78 M -35.3 M -42.4 M -59.7 M -21.8 M -6.83 M -186 K -1.37 M 208 K - - - - -

Long Term Debt

411 K 15 M 397 K 9.7 M 15 M - - - - - - - - - -

Long Term Debt Current

623 K 140 K 119 K 87 K 72 K 33.9 K 8.29 K - - - - - - - -

Total Non Current Liabilities

411 K 244 K 397 K 10.8 M 15.4 M 126 K 160 K - - - - - - - -

Total Current Liabilities

8.42 M 7.22 M 18.5 M 10.9 M 4.36 M 1.78 M 700 K 824 K - - - - - - -

Total Liabilities

8.83 M 7.46 M 18.9 M 21.7 M 19.7 M 1.9 M 861 K 824 K 310 K 601 K - - - - -

Retained Earnings

-209 M -163 M -121 M -91 M -63.7 M -33.4 M -21.3 M -13.6 M -1.16 M -326 K - - - - -

Total Assets

32.4 M 39.6 M 57 M 81.8 M 99.9 M 40.7 M 24.5 M 17.4 M 18.4 M 452 K - - - - -

Cash and Cash Equivalents

24.8 M 20.9 M 35.8 M 52.2 M 74.8 M 22 M 7 M 186 K 1.37 M - - - - - -

Book Value

23.5 M 32.1 M 38.1 M 60.1 M 80.2 M 38.8 M 23.6 M 16.5 M 18.1 M -149 K - - - - -

Total Shareholders Equity

23.5 M 32.1 M 37.3 M 60.1 M 80.2 M 38.8 M 23.6 M 16.5 M 18.1 M - - - - - -

All numbers in USD currency

Quarterly Balance Sheet INmune Bio

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

518 K 593 K 806 K 411 K 623 K 231 K 201 K 244 K 284 K 322 K - 397 K 430 K 463 K 498 K 526 K 607 K - 684 K 284 K 95 K 106 K 116 K 126 K 136 K 145 K 154 K 160 K 172 K 177 K 160 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

518 K 593 K 806 K 411 K 623 K 231 K 201 K 244 K 284 K 322 K - 397 K 3.61 M 6.01 M 8.4 M 10.8 M 13.2 M - 15.5 M 15.4 M 14.6 M 14.5 M 116 K 126 K 136 K 145 K 154 K 160 K 172 K 177 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

3.44 M 6.48 M 6.19 M 8.83 M 7.98 M 8.82 M 8.13 M 7.46 M 14.1 M 15.4 M - 18.9 M 18 M 19.1 M 18.7 M 21.7 M 20.1 M - 18.7 M 19.7 M 19.4 M 17.5 M 2.31 M 1.9 M 1.61 M 1.36 M 1.27 M 861 K 687 K 693 K 781 K 824 K 824 K 824 K 824 K 310 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-220 M -216 M -214 M -209 M -204 M -197 M -173 M -163 M -154 M -142 M - -121 M -113 M -104 M -97.6 M -91 M -85.2 M - -70.6 M -63.7 M -54 M -44.6 M -37.9 M -33.4 M -30.2 M -25.5 M -23.3 M -21.3 M -19 M -15.9 M -15.5 M -13.6 M -13.6 M -13.6 M -13.6 M -1.16 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

21.5 M 26.8 M 25.8 M 32.4 M 33.4 M 37.7 M 37.8 M 39.6 M 52.8 M 52.5 M - 57 M 62.7 M 69.7 M 74 M 81.8 M 83.8 M - 94.4 M 99.9 M 108 M 60.7 M 65.9 M 40.7 M 42.8 M 23 M 23.7 M 24.5 M 25.4 M 27.5 M 23.6 M 17.4 M 17.4 M 17.4 M 17.4 M 18.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

16.3 M 18.4 M 21.4 M 24.8 M 27.7 M 33.4 M 19.3 M 20.9 M 33.6 M 31.1 M 26 M 35.8 M 41.8 M 47.8 M 51 M 52.2 M 57.4 M 61.2 M 66.7 M 74.8 M 84.5 M 39.5 M 45.3 M 22 M 24.3 M 4.82 M 5.93 M 7 M 7.38 M 9.36 M 6.05 M 186 K 186 K 186 K 186 K 1.37 M - - - 142 K - - - - - - - - - - - - - - - - - - - - - - -

Book Value

18.1 M 20.4 M 19.6 M 23.5 M 25.4 M 28.9 M 29.7 M 32.1 M 38.7 M 37.1 M - 38.1 M 44.7 M 50.7 M 55.3 M 60.1 M 63.7 M - 75.6 M 80.2 M 88.3 M 43.2 M 63.6 M 38.8 M 41.2 M 21.7 M 22.4 M 23.6 M 24.7 M 26.8 M 22.9 M 16.5 M 16.5 M 16.5 M 16.5 M 18.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

18.1 M 20.4 M 19.6 M 23.5 M 25.4 M 28.9 M 29.7 M 32.1 M 38.7 M 36.3 M 28.2 M 37.3 M 43.9 M 50.7 M 55.3 M 60.1 M 63.7 M 69.9 M 75.6 M 80.2 M 88.3 M 43.2 M 63.6 M 38.8 M 41.2 M 21.7 M 22.4 M 23.6 M 24.7 M 26.8 M 22.9 M 16.5 M 16.5 M 16.5 M 16.5 M 18.1 M - - - -149 K - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of INmune Bio, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA